Polymorphisms in PPAR Genes (PPARD, PPARG, and PPARGC1A) and the Risk of Chronic Kidney Disease in Japanese: Cross-Sectional Data from the J-MICC Study
Table 2
PPARD, PPARG, and PPARGC1A polymorphisms and risk of CKD.
Polymorphism
Genotype
CKD (+)
CKD (−)
aOR (95% CI)
Trend P*
(n = 575)
(n = 2,740)
PPARD A65G in exon 7 (Asn163Asn) (rs2076167)
A/A
331 (57.6%)
1,681 (61.4%)
Reference
G/A
214 (37.2%)
929 (33.9%)
1.20 (0.98–1.45)
0.079
G/G
30 (5.2%)
130 (4.7%)
1.20 (0.78–1.83)
G/A + G/G
244 (42.4%)
1059 (38.6%)
1.20 (0.99–1.44)
PPARD T-48444C in exon 3 (rs6902123)
T/T
559 (97.2%)
2,628 (95.9%)
Reference
C/T
16 (2.8%)
110 (4.0%)
0.71 (0.41–1.22)
0.174
C/C
0 (0.0%)
2 (0.1%)
0 (−)
C/T + C/C
16 (2.8%)
112 (4.1%)
0.70 (0.40–1.20)
PPARD T-842C in exon 3 (rs2267668)
T/T
342 (59.5%)
1,776 (64.8%)
Reference
C/T
207 (36.0%)
855 (31.2%)
1.26 (1.04–1.53)
0.018
C/C
26 (4.5%)
109 (4.0%)
1.31 (0.83–2.06)
C/T + C/C
233 (40.5%)
964 (35.2%)
1.27 (1.05–1.53)
PPARG C161T (His477His) (rs3856806)
C/C
401 (69.7%)
1,968 (71.8%)
Reference
C/T
164 (28.5%)
719 (26.2%)
1.12 (0.91–1.38)
0.463
T/T
10 (1.7%)
53 (1.9%)
0.88 (0.44–1.76)
C/T + C/C
174 (30.3%)
772 (28.1%)
1.10 (0.68–1.00)
PPARG Pro12Ala (rs1801282)
G/G
535 (93.0%)
2,578 (94.1%)
Reference
C/G
38 (6.6%)
160 (5.8%)
1.17 (0.80–1.70)
0.216
C/C
2 (0.3%)
2 (0.1%)
4.69 (0.62–35.51)
C/G + C/C
40 (6.9%)
162 (5.9%)
1.21 (0.84–1.75)
PPARGC1A Thr394Thr (rs2970847)
C/C
372 (64.7%)
1,661 (60.6%)
Reference
C/T
170 (29.6%)
946 (34.5%)
0.79 (0.64–0.97)
0.223
T/T
33 (5.7%)
133 (4.9%)
1.13 (0.75–1.70)
C/T + T/T
203 (35.3%)
1,079 (39.4%)
0.83 (0.68–1.00)
PPARGC1A Gly482Ser (rs8192678)
G/G
162 (28.2%)
788 (28.8%)
Reference
A/G
275 (47.8%)
1,390 (50.7%)
0.96 (0.78–1.20)
0.151
A/A
138 (24.0%)
562 (20.5%)
1.23 (0.95–1.59)
A/G + A/A
413 (71.8%)
1,952 (71.2%)
1.04 (0.85–1.27)
aOR: adjusted odds ratio (adjusted for age and sex); CKD: chronic kidney disease. Adjusted for age and sex.
